May 2004
Volume 45, Issue 13
ARVO Annual Meeting Abstract  |   May 2004
Prevalence of age–related maculopathy in the EUREYE study
Author Affiliations & Notes
  • C. Augood
    Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom
  • A.E. Fletcher
    Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom
  • U. Chakravarthy
    Ophthalmology and Vision Science, Queen's University, Belfast, United Kingdom
  • P. De Jong
    Netherlands Institute for Ophthalmic Research, KNAW, Amsterdam, The Netherlands
  • M. Rahu
    Institute of Experimental and Clinical Medicine, Tallinn, Estonia
  • J. Seland
    Oyeavdelingen, Haukeland Sykehus, University of Bergen, Bergen, Norway
  • G. Soubrane
    Clinique Ophthalmologique, Universitaire de Creteil, Paris, France
  • L. Tomazzoli
    Clinica Oculistica, Universita degli studi di Verona,, Verona, Italy
  • F. Topouzis
    Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece
  • J. Vioque
    Dpto Salud Publica,, Universidad Miguel Hernandez, Alicante, Spain
  • Footnotes
    Commercial Relationships  C. Augood, None; A.E. Fletcher, None; U. Chakravarthy, None; P. De Jong, None; M. Rahu, None; J. Seland, None; G. Soubrane, None; L. Tomazzoli, None; F. Topouzis, None; J. Vioque, None.
  • Footnotes
    Support  European Commission Vth Framework (QLK6–CT–1999–02094), Macular Disease Society UK
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 3048. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. Augood, A.E. Fletcher, U. Chakravarthy, P. De Jong, M. Rahu, J. Seland, G. Soubrane, L. Tomazzoli, F. Topouzis, J. Vioque; Prevalence of age–related maculopathy in the EUREYE study . Invest. Ophthalmol. Vis. Sci. 2004;45(13):3048.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To estimate the prevalence of age related maculopathy in an older population from 7 European countries Methods: Randomly sampled people aged 65 and over were invited to an eye examination and risk factor assessment in seven centres across Europe(Norway, Estonia, UK, France, Italy, Greece and Spain). Two non–simultaneous 350stereoscopic colour fundus images centred were taken for each eye and graded at a single reading centre by the International ARM Epidemiological Study Group classification using grading in the worst eye. Overall, age and sex specific rates were calculated for stage of ARM with 95% confidence intervals (CIs) calculated for clustered data. Multinomial modelling was used to assess the associations (relative risk ratio, RRR) of gender with stage of ARM. Results: 4760 people (2142 men and 2618 women) (50% response rate) had gradeable fundus images. The % prevalences (95% CIs) were : Stage 0 : 47.6, (43.6 to 51.6), Stage 1 :36.5 (32.9 to 40.3), Stage 2: 10.2 (9.0 to11.5), Stage 3: 2.5 (1.9 to 3.2), Stage 4 (AMD) :3.3 (2.6 to 4.2). Prevalence of Stages 2, 3 and, especially, of stage 4 (AMD) rose steeply with age. The age specific prevalences of AMD were 65–69: 1.0 (0.6 to 1.7), 70–74: 2.2 (1.5 to 3.3), 75–79: 3.6 (2.5 to 5.1), 80+: 12.1(8.3 to 17.3). Compared to men, age adjusted prevalences were lower for women for Stage 2, RRR = 0.77 (95% CI 0.67 to 0.87) p=0.002 and higher for AMD, RRR= 1.40 (95% CI 1.05 to 1.86) p=0.03. After adjustment for smoking, the RRRs for women for stage 2 were unchanged while for AMD the RRR increased to 1.89 (1.55 to 2.30) p=0.0001. Conclusions:The prevalence of age related maculopathy in the EUREYE study is of a similar magnitude to other population based studies in western populations. This study also found an excess of AMD in women observed in some, but not all studies.

Keywords: age–related macular degeneration • clinical (human) or epidemiologic studies: prevalence/incidence 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.